Melissa Ilg
Psychiatric/Mental Health · Culver, INNPI 1225083371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,950 of the $7,716 with a category attached, or 64.1%. AbbVie accounts for 69.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $2,916 and has fallen 58.3% since, to $1,216 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $54.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$418
- Teva Pharmaceuticals USA, Inc.$370
- Otsuka America Pharmaceutical, Inc.$361
- Vanda Pharmaceuticals Inc.$221
- Neurocrine Biosciences, Inc.$203
- plus $753 from 10 others
What the payments were for
- Speaking & faculty fees$4,95064%
- Travel & lodging$1432%
- Food & beverage$2,57533%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $5,390 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $418 |
| Teva Pharmaceuticals USA, Inc. | 18 | $370 |
| Otsuka America Pharmaceutical, Inc. | 19 | $361 |
| Vanda Pharmaceuticals Inc. | 6 | $221 |
| Neurocrine Biosciences, Inc. | 12 | $203 |
| Lundbeck LLC | 13 | $184 |
| Alkermes, Inc. | 9 | $167 |
| Axsome Therapeutics, Inc. | 7 | $146 |
| Johnson & Johnson | 4 | $83 |
| Supernus Pharmaceuticals, Inc. | 2 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Eisai Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Indivior Inc. | 1 | $11 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$4,950
How this compares
$7,716 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $255,091 |
| Abilify MaintenaAripiprazole | 32 | $84,429 |
| VraylarCariprazine Hcl | 36 | $57,591 |
| NuplazidPimavanserin Tartrate | 13 | $54,170 |
| CaplytaLumateperone Tosylate | 28 | $54,104 |
| RexultiBrexpiprazole | 19 | $38,956 |
| Aripiprazole | 73 | $13,445 |
| BelsomraSuvorexant | 12 | $5,015 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 36 | $4,577 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,465 |
| Lurasidone Hcl | 16 | $2,343 |
| Buspirone Hcl | 89 | $1,872 |
| Guanfacine Hcl ErGuanfacine Hcl | 48 | $1,509 |
| Lamotrigine | 84 | $986 |
| Clozapine | 11 | $924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $203 | $255,09131 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $361 | $123,38451 claims |
| AbbVieVraylar | $5,390 | $57,59136 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $418 | $54,10428 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $14 | $4,46512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Culver
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.